ROIVANT SCIENCES LTD. Net Income
ROIVANT SCIENCES LTD. (ROIV) reported Net Income of -$189.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$189.84M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $302.99M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$265.89M, a 256.98% decline year-over-year.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$113.52M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for fiscal 2026 was -$299.77M.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for fiscal 2025 was -$171.98M, a 103.95% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for fiscal 2024 was $4.35B.
- ROIVANT SCIENCES LTD. net income (loss) attributable to parent for fiscal 2023 was -$1.01B.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$189.84M 10-Q · filed 2026-08-06 | $113.16M derived: sum of 2 quarters · filed 2026-08-06 | -$152.73M derived: sum of 3 quarters · filed 2026-08-06 | -$266.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $302.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $37.10M derived: sum of 2 quarters · filed 2026-05-20 | -$76.42M derived: sum of 3 quarters · filed 2026-05-20 | -$299.77M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$265.89M 10-Q · filed 2026-02-06 | -$379.41M derived: sum of 2 quarters · filed 2026-02-06 | -$602.76M 10-Q · filed 2026-02-06 | -$809.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$113.52M 10-Q · filed 2025-11-10 | -$336.87M 10-Q · filed 2025-11-10 | -$543.35M derived: sum of 3 quarters · filed 2026-08-06 | -$373.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$223.35M 10-Q · filed 2026-08-06 | -$429.83M derived: sum of 2 quarters · filed 2026-08-06 | -$260.45M derived: sum of 3 quarters · filed 2026-08-06 | -$490.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$206.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$37.09M derived: sum of 2 quarters · filed 2026-05-20 | -$267.28M derived: sum of 3 quarters · filed 2026-05-20 | -$171.98M 10-K · filed 2026-05-20 |
| 2024-12-31 | $169.38M 10-Q · filed 2026-02-06 | -$60.80M derived: sum of 2 quarters · filed 2026-02-06 | $34.49M 10-Q · filed 2026-02-06 | -$116.62M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$230.18M 10-Q · filed 2025-11-10 | -$134.89M 10-Q · filed 2025-11-10 | -$286.00M derived: sum of 3 quarters · filed 2026-05-20 | $4.81B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $95.30M 10-Q · filed 2025-08-11 | -$55.82M derived: sum of 2 quarters · filed 2026-05-20 | $5.04B derived: sum of 3 quarters · filed 2026-05-20 | $4.74B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$151.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $4.95B derived: sum of 2 quarters · filed 2026-05-20 | $4.64B derived: sum of 3 quarters · filed 2026-05-20 | $4.35B 10-K · filed 2026-05-20 |
| 2023-12-31 | $5.10B 10-Q · filed 2025-02-10 | $4.79B derived: sum of 2 quarters · filed 2025-02-10 | $4.50B 10-Q · filed 2025-02-10 | $4.47B derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$304.33M 10-Q · filed 2024-11-12 | -$596.14M 10-Q · filed 2024-11-12 | -$629.76M derived: sum of 3 quarters · filed 2025-05-29 | -$981.77M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$291.82M 10-Q · filed 2024-08-09 | -$325.43M derived: sum of 2 quarters · filed 2025-05-29 | -$677.45M derived: sum of 3 quarters · filed 2025-05-29 | -$969.04M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$33.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$385.63M derived: sum of 2 quarters · filed 2025-05-29 | -$677.22M derived: sum of 3 quarters · filed 2025-05-29 | -$1.01B 10-K · filed 2025-05-29 |
| 2022-12-31 | -$352.01M 10-Q · filed 2024-02-13 | -$643.60M derived: sum of 2 quarters · filed 2024-02-13 | -$975.41M 10-Q · filed 2024-02-13 | -$1.25B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$291.59M 10-Q · filed 2023-11-13 | -$623.40M 10-Q · filed 2023-11-13 | -$893.46M derived: sum of 3 quarters · filed 2023-11-13 | -$1.18B derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$331.81M 10-Q · filed 2023-08-14 | -$601.87M derived: sum of 2 quarters · filed 2023-08-14 | -$886.41M derived: sum of 3 quarters · filed 2023-08-14 | -$1.09B derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$270.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$554.60M derived: sum of 2 quarters · filed 2023-06-28 | -$763.08M derived: sum of 3 quarters · filed 2023-06-28 | -$845.26M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$284.54M 10-Q · filed 2023-02-13 | -$493.02M derived: sum of 2 quarters · filed 2023-02-13 | -$575.20M 10-Q · filed 2023-02-13 | -$1.08B derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | -$208.48M 10-Q · filed 2022-11-14 | -$290.66M 10-Q · filed 2022-11-14 | -$800.23M derived: sum of 3 quarters · filed 2022-11-14 | -$1.06B derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$82.18M 10-Q · filed 2022-08-15 | -$591.75M derived: sum of 2 quarters · filed 2022-08-15 | -$852.78M derived: sum of 3 quarters · filed 2022-08-15 | -$888.17M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$509.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$770.59M derived: sum of 2 quarters · filed 2022-06-28 | -$805.99M derived: sum of 3 quarters · filed 2022-06-28 | -$809.23M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$261.03M 10-Q · filed 2022-02-14 | -$296.43M derived: sum of 2 quarters · filed 2022-02-14 | -$299.67M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$35.40M 10-Q · filed 2021-11-15 | -$38.64M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$3.24M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |